KRYS vs. IMVT, CRSP, HALO, IBRX, SWTX, IOVA, RVMD, DNLI, IMCR, and TWST
Should you be buying Krystal Biotech stock or one of its competitors? The main competitors of Krystal Biotech include Immunovant (IMVT), CRISPR Therapeutics (CRSP), Halozyme Therapeutics (HALO), ImmunityBio (IBRX), SpringWorks Therapeutics (SWTX), Iovance Biotherapeutics (IOVA), Revolution Medicines (RVMD), Denali Therapeutics (DNLI), Immunocore (IMCR), and Twist Bioscience (TWST). These companies are all part of the "biological products, except diagnostic" industry.
Immunovant (NASDAQ:IMVT) and Krystal Biotech (NASDAQ:KRYS) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings, valuation and community ranking.
Immunovant's return on equity of -5.74% beat Krystal Biotech's return on equity.
Immunovant currently has a consensus price target of $48.00, suggesting a potential upside of 55.49%. Krystal Biotech has a consensus price target of $177.63, suggesting a potential upside of 8.01%. Given Krystal Biotech's higher possible upside, equities research analysts plainly believe Immunovant is more favorable than Krystal Biotech.
In the previous week, Krystal Biotech had 3 more articles in the media than Immunovant. MarketBeat recorded 9 mentions for Krystal Biotech and 6 mentions for Immunovant. Krystal Biotech's average media sentiment score of 0.89 beat Immunovant's score of 0.72 indicating that Immunovant is being referred to more favorably in the media.
Immunovant has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.
47.1% of Immunovant shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 4.8% of Immunovant shares are owned by company insiders. Comparatively, 14.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Krystal Biotech received 169 more outperform votes than Immunovant when rated by MarketBeat users. However, 76.22% of users gave Immunovant an outperform vote while only 66.83% of users gave Krystal Biotech an outperform vote.
Krystal Biotech has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
Summary
Krystal Biotech beats Immunovant on 11 of the 15 factors compared between the two stocks.
Get Krystal Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for KRYS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KRYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Krystal Biotech Competitors List
Related Companies and Tools
